Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bee venom therapy (BVT) has roots in traditional medicine, particularly in Asia and Eastern Europe, but recently has gained attention for potential use in autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. The primary component of bee venom, melittin, possesses anti-inflammatory and immunomodulatory properties, which have been studied in both animal models and limited human clinical trials. Research suggests that bee venom may reduce inflammation by inhibiting pro-inflammatory cytokines and modulating immune cell activity. Small-scale clinical studies, especially in rheumatoid arthritis, have reported symptom improvement, reduced swelling, and decreased pain. However, these studies often suffer from methodological limitations such as small sample sizes, lack of blinding, or inadequate controls. Systematic reviews and meta-analyses conclude that while there is some promising data, the overall quality of evidence is low and insufficient to recommend bee venom therapy as a standard treatment for autoimmune disorders. Furthermore, there is a significant risk of allergic reactions, including anaphylaxis, which limits its widespread use. More rigorous, larger-scale, placebo-controlled trials are necessary to confirm efficacy and safety. In summary, there is preliminary scientific evidence supporting bee venom's potential benefit in autoimmune conditions, but current evidence is weak and not yet sufficient for routine clinical use.

More about bee venom
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by bee venom

Products containing bee venom